Gordon, J., Danne, T., Beresford-Hulme, L., Bennet, H., Tank, A., Edmonds, C., . . . McEwan, P. (2020). Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme. Diabetes Ther.
Chicago Style citaatGordon, Jason, Thomas Danne, Lee Beresford-Hulme, Hayley Bennet, Amarjeet Tank, Christopher Edmonds, Fredrik Thorén, Markus Florian Scheerer, en Phil McEwan. "Adverse Changes in HbA1c, Body Weight and Insulin Use in People With Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme." Diabetes Ther 2020.
MLA citatieGordon, Jason, et al. "Adverse Changes in HbA1c, Body Weight and Insulin Use in People With Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme." Diabetes Ther 2020.